Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of …
Over the last 12 months, insiders at Cognition Therapeutics, Inc. have bought $9,975 and sold $0 worth of Cognition Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cognition Therapeutics, Inc. have bought $3.75M and sold $4,818 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ricciardi Lisa (CEO & President) — $19,950.
The last purchase of 5,700 shares for transaction amount of $9,975 was made by Ricciardi Lisa (CEO & President) on 2024‑03‑14.
2024-03-14 | CEO & President | 5,700 0.0172% | $1.75 | $9,975 | -53.48% | |||
2022-11-29 | director | 10,000 0.0453% | $2.65 | $26,550 | -29.84% | |||
2022-11-28 | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | |||
2022-11-28 | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | |||
2022-11-16 | director | 71,000 0.3069% | $1.40 | $99,400 | +27.37% | |||
2022-11-16 | director | 71,000 0.3069% | $1.40 | $99,400 | +27.37% | |||
2022-11-15 | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.34% | |||
2022-11-15 | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.34% | |||
2022-11-15 | director | 12,500 0.0438% | $1.20 | $15,000 | +20.34% | |||
2022-11-15 | CEO & President | 12,000 0.0455% | $1.30 | $15,600 | +20.34% | |||
2021-10-13 | Sale | 10 percent owner | 74.05 0.0014% | $12.00 | $889 | -76.39% | ||
2021-10-13 | Sale | 10 percent owner | 33.09 0.0006% | $12.00 | $397 | -76.39% | ||
2021-10-13 | Sale | director | 23.48 0.0004% | $12.00 | $282 | -76.39% | ||
2021-10-13 | Sale | director | 180.56 0.0034% | $12.00 | $2,167 | -76.39% | ||
2021-10-13 | Sale | 10 percent owner | 90.28 0.0017% | $12.00 | $1,083 | -76.39% | ||
2021-10-13 | director | 380,000 7.2005% | $12.00 | $4.56M | -76.39% | |||
2021-10-13 | 10 percent owner | 190,000 3.6003% | $12.00 | $2.28M | -76.39% | |||
2021-10-13 | CEO & President | 25,000 0.4737% | $12.00 | $300,000 | -76.39% | |||
2021-10-13 | Chief Financial Officer | 10,000 0.1895% | $12.00 | $120,000 | -76.39% | |||
2021-10-13 | director | 3,000 0.0568% | $12.00 | $36,000 | -76.39% |
Ricciardi Lisa | CEO & President | 291345 0.7012% | $0.62 | 3 | 0 | <0.0001% |
Fletcher Aaron G.L. | director | 2021906 4.8664% | $0.62 | 4 | 1 | <0.0001% |
Kreis Leslie W. | director | 2021906 4.8664% | $0.62 | 3 | 0 | +5.32% |
BIOS Memory SPV I, LP | 10 percent owner | 899905 2.1659% | $0.62 | 1 | 1 | <0.0001% |
Wallace Peggy | director | 37961 0.0914% | $0.62 | 2 | 0 | <0.0001% |
Aigh Capital Management Llc | $3.45M | 4.74 | 1.9M | -6.94% | -$257,675.61 | 1.97 | |
The Vanguard Group | $1.68M | 2.3 | 921,680 | +27.73% | +$364,229.41 | <0.0001 | |
Awm Investment Company Inc | $1.18M | 1.62 | 650,000 | New | +$1.18M | 0.18 | |
Alyeska Investment Group L P | $910,000.00 | 1.25 | 500,000 | New | +$910,000.00 | 0.01 | |
Timelo Investment Management Inc. | $874,839.00 | 1.2 | 480,681 | New | +$874,839.00 | 1.6 |